loading...| Preferred Name |
Paritaprevir |
|
| Synonyms |
|
|
| Definitions |
An orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, and infection is associated with the development of hepatocellular carcinoma (HCC). |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C123879 |
|
| CAS_Registry |
1216941-48-8 |
|
| code |
C123879 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
An orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, and infection is associated with the development of hepatocellular carcinoma (HCC). |
|
| Display_Name |
Paritaprevir |
|
| FDA_UNII_Code |
OU2YM37K86 |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 |
|
| label |
Paritaprevir |
|
| Preferred_Name |
Paritaprevir |
|
| prefixIRI |
NCIT:C123879 |
|
| prefLabel |
Paritaprevir |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C3712108 |
|
| subClassOf |